Chloroquine (CQ) was used with AP/ES (anti-EGFR Aptamers- modified polyamidoamine) to restore tumor vasculature to provide optimal drug/gene delivery and overcome treatment resistance in NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.